Keywords: alkermes, shares, hit, decision, drop, extended-release, form
Alkermes shares hit by J&J decision to drop extended-release form of EPO
Article | 13 June 2000
Johnson & Johnson has terminated further development of an injectablesustained-release formulation of its erythropoietin drug Procrit/Eprex (epoetin alfa) based on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
